secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0002007919-24-000054
Event type: litigation
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx wins trade secrets trial against I-Mab; jury rejects all misappropriation claims
--------------------------------------------------------------------------------

- Jury found in favor of Inhibrx, rejecting I-Mab's allegations of misappropriation of trade secrets.
- Lawsuit filed March 1, 2022, claimed Inhibrx and CSO Brendan Eckelman improperly used I-Mab's proprietary info.
- Certain matters remain before the court; Inhibrx notes potential appeals or further proceedings.
- The verdict removes a significant legal overhang for Inhibrx.
- Inhibrx announced the jury verdict on November 4, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791924000054/0002007919-24-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791924000054/inhibrx-20241104.htm
  HTML page:      https://secwatch.observer/filing/0002007919-24-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer